Diagnamed Holdings Corp. (DGNMF)

Diagnamed Holdings Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cost of Revenue	-	-	-	0.02	0.02
Gross Profit	-	-	-	-0.02	-0.02
Selling, General & Admin	0.2	0.43	0.81	0.41	0.47
Research & Development	0.26	0.25	0.35	0.56	0.2
Operating Expenses	0.56	0.67	1.18	1.11	0.67
Operating Income	-0.56	-0.67	-1.18	-1.14	-0.68
Interest & Investment Income	-	0.01	0.01	-	-
Currency Exchange Gain (Loss)	-0.05	0.01	0.02	0	-
Other Non Operating Income (Expenses)	-0.1	-0.07	-0.08	-	-
EBT Excluding Unusual Items	-0.75	-0.72	-1.23	-1.13	-0.68
Other Unusual Items	-0.03	0.22	-0.05	-	-1.26
Pretax Income	-0.79	-0.5	-1.28	-1.13	-1.95
Net Income	-0.79	-0.5	-1.28	-1.13	-1.95
Net Income to Common	-0.79	-0.5	-1.28	-1.13	-1.95
Shares Outstanding (Basic)	81	80	78	76	56
Shares Outstanding (Diluted)	81	80	78	76	56
Shares Change (YoY)	1.39%	2.38%	2.81%	36.38%	-
EPS (Basic)	-0.01	-0.01	-0.02	-0.01	-0.03
EPS (Diluted)	-0.01	-0.01	-0.02	-0.01	-0.03
EBIT	-0.56	-0.67	-1.18	-1.14	-0.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.